- Home
- RMBI vs SLN Comparison
RMBI vs SLN Comparison
Compare RMBI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- SLN
- Stock Information
- Founded
- RMBI 1887
- SLN 1994
- Country
- RMBI United States
- SLN United Kingdom
- Employees
- RMBI N/A
- SLN N/A
- Industry
- RMBI Major Banks
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- SLN Health Care
- Exchange
- RMBI Nasdaq
- SLN Nasdaq
- Market Cap
- RMBI 140.8M
- SLN 165.3M
- IPO Year
- RMBI 2019
- SLN N/A
- Fundamental
- Price
- RMBI $13.55
- SLN $5.68
- Analyst Decision
- RMBI
- SLN Buy
- Analyst Count
- RMBI 0
- SLN 5
- Target Price
- RMBI N/A
- SLN $32.60
- AVG Volume (30 Days)
- RMBI 55.3K
- SLN 123.0K
- Earning Date
- RMBI 07-24-2025
- SLN 08-14-2025
- Dividend Yield
- RMBI 4.54%
- SLN N/A
- EPS Growth
- RMBI 2.54
- SLN N/A
- EPS
- RMBI 0.89
- SLN N/A
- Revenue
- RMBI $42,825,687.00
- SLN $27,701,000.00
- Revenue This Year
- RMBI N/A
- SLN N/A
- Revenue Next Year
- RMBI N/A
- SLN N/A
- P/E Ratio
- RMBI $14.91
- SLN N/A
- Revenue Growth
- RMBI 2.64
- SLN N/A
- 52 Week Low
- RMBI $11.26
- SLN $1.97
- 52 Week High
- RMBI $15.15
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- RMBI 50.00
- SLN 59.55
- Support Level
- RMBI $13.03
- SLN $5.69
- Resistance Level
- RMBI $13.91
- SLN $6.25
- Average True Range (ATR)
- RMBI 0.57
- SLN 0.46
- MACD
- RMBI -0.00
- SLN -0.01
- Stochastic Oscillator
- RMBI 54.26
- SLN 64.00
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.